Sudarshan Sukhani of s2analytics.com is of the view that one can short Punjab National Bank and can buy Aurobindo Pharma, Dr Reddy's Laboratories and Prabhat Dairy.
According to filing with the US Securities and Exchange Commission, the city-based pharma company is expected to file the New Drug Application (NDA) with US Food and Drug Administration with regard the migraine drug in 2018 while it is expected to submit license application for the cancer drug, it may approach the drug regulator in 2019.
According to Prakash Gaba of prakashgaba.com, one may remain invested in Dr Reddy's Laboratories.
Sharekhan remains cautious on pharma sector.
CLSA has maintained its buy call on Dr Reddy's, with a target price of Rs 3,280. It feels biosimilars will drive scale-up in emerging markets.
Mitessh Thakkar of mitesshthakkar.com suggests buying Dr Reddy's Laboratories and selling Exide Industries.
Rajat Bose of rajatkbose.com advises selling Hindustan Petroleum Corporation and suggests buying Aurobindo Pharma, Dr Reddy's Laboratories.
The drug is manufactured by pharma firm Cipla at its Pune facility for Dr Reddy's Laboratories.
Mitessh Thakkar of mitesshthakkar.com advises buying Dr Reddy's Laboratories and Engineers India.
"In that regard, we would now like to inform you that we have received an establishment inspection report (EIR) from the USFDA today as closure of audit for the above referred facility," the drug maker said its filing last night.
Yogesh Mehta of Motilal Oswal is of the view that one may buy Dr Reddy’s Laboratories and Dewan Housing Finance.
Sudarshan Sukhani of s2analytics.com advises buying Dr Reddy's Laboratories.
According to Mitessh Thakkar of mitesshthakkar.com, one may sell Canara Bank and Ceat.
Dr Reddy's Labs received establishment inspection report from the US health regulator for its Miryalaguda plant.
A spotlight on Dr. Reddy's Laboratories (DRL), a big relief comes in from the US drug regulator for its active pharmaceutical ingredients (API) plant Miryalaguda.
Ashwani Gujral of ashwanigujral.com suggests buying Tata Motors DVR, SREI Infrastructure Finance and Dr Reddy's Laboratories.
In a BSE filing, Dr Reddy's said it has "launched Bivalirudin for injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax for injection, approved by the US Food and Drug Administration (USFDA)".
Ashwani Gujral of ashwanigujral.com suggests buying UPL, Dr Reddy's Laboratories and Adani Ports and Special Economic Zone.
The United States Food and Drug Administration (USFDA) has completed the audit of company’s formulations Srikakulum plant (SEZ) unit II, Andhra Pradesh with zero observations.
The Department of Science and Technology (DST), Dr Reddy's Laboratories (DRL) and University of Hyderabad (UoH) have joined hands to initiate a project on discovery and development of anti-psoriatic drugs.
Individual news flow along with negative outlook for the sector by Credit Suisse hit the sector. Frontline stocks tank, pulling down the markets further.
The approval from the US Food and Drug Administration (USFDA) for doxorubicin hydrochloride liposome intravenous injection is an outcome of extensive collaboration with the company's partner Natco Pharma on research and development and manufacturing capabilities, Dr Reddy's said in a BSE filing.
ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 2610 in its research report dated May 15, 2017.
Dr Reddy's Laboratories | Infosys | Premier Explosives | Brigade Enterprises | Tata Motors | Colgate | JK Tyre | Bata India | Sutlej Textiles | Skipper and Indo Count Industries are stocks, which are in news today.
Edelweiss recommended hold rating on Dr. Reddys Laboratories with a target price of Rs 2660 in its research report dated May 12, 2017.